RT3 – GLP3: Triple-Agonist Peptide Research Guide (2026)

<p>RT3 – GLP3 (LY3437943) is a synthetic peptide developed by Eli Lilly and Company that functions as a triple agonist at the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (GCGR) receptor. This tri-receptor engagement distinguishes RT3 – GLP3 from earlier dual-agonist compounds such as TZ2 – GLP2 and has made it a subject of significant interest in metabolic and energy homeostasis research.</p><p>As of 2026, RT3 – GLP3 is in Phase 3 clinical development. Research-grade RT3 – GLP3 is investigated in laboratory settings to study the molecular interactions of simultaneous GLP-1R, GIPR, and GCGR engagement.</p><h2>Molecular Profile</h2><p>Molecular Weight: approximately 4.7 kDa | Classification: Incretin-class triple receptor agonist research peptide | CAS: 2381928-68-1</p><p>RT3 – GLP3 incorporates a fatty acid side chain enabling extended albumin binding, similar in concept to TZ2 – GLP2's structural approach, while adding glucagon receptor engagement — a pathway not activated by earlier GLP-1 compounds.</p><h2>Triple Receptor Mechanism</h2><h3>Glucagon Receptor (GCGR) Addition</h3><p>The addition of glucagon receptor agonism is the defining pharmacological feature distinguishing RT3 – GLP3 from dual-agonist predecessors. GCGR activation has been studied for its role in energy expenditure and hepatic glucose production. In preclinical models, GCGR engagement has shown effects on thermogenesis and fat oxidation pathways — areas of active metabolic research. The combination of GCGR activation with GIP and GLP-1 agonism creates a tri-pathway engagement model researchers use to study energy balance mechanisms.</p><h3>GLP-1R and GIPR Activity</h3><p>As with TZ2 – GLP2, RT3 – GLP3 activates GLP-1 and GIP receptors. Published Phase 2 trial data from the NEJM 2023 publication documented significant effects on body weight and glucose metabolism in a human study population — data that informs preclinical model design and pathway hypothesis development.</p><p>↗ Jastreboff et al. (2023). Triple-Hormone-Receptor Agonist RT3 – GLP3 for Obesity. NEJM. DOI: 10.1056/NEJMoa2301972</p><h2>Published Phase 2 Data — Research Reference</h2><p>The Phase 2 NEJM publication (Jastreboff et al., 2023) is the primary published reference for RT3 – GLP3's biological effects in a human study. Key findings from this 48-week study inform laboratory model design:</p><ul><li>Dose-dependent weight reduction observed across multiple dosing cohorts</li><li>Effects on fasting glucose, insulin sensitivity indices</li><li>Gastrointestinal tolerability data relevant to dosing model design</li><li>Cardiovascular marker changes documented as secondary endpoints</li></ul><p>This trial data does not constitute evidence of efficacy for any specific condition and is referenced here as published scientific literature informing the research context.</p><h2>Research Applications in Laboratory Settings</h2><ul><li>Comparative triple vs. dual vs. single receptor agonism studies</li><li>GCGR signaling pathway investigation in cell culture</li><li>Energy expenditure pathway research in preclinical models</li><li>Hepatic glucose production pathway studies</li><li>Adipose tissue biology research models</li><li>GLP-1R / GIPR / GCGR receptor binding affinity studies</li></ul><h2>Specifications and Purity Requirements</h2><p>RT3 – GLP3 is a structurally complex peptide. Research-grade material must be verified by:</p><ul><li>HPLC purity ≥99% from an accredited independent laboratory</li><li>LC-MS confirming correct molecular weight and sequence integrity</li><li>Batch-specific COA documentation</li></ul><h2>Frequently Asked Questions</h2><p>Q: What makes RT3 – GLP3 different from TZ2 – GLP2?</p><p>A: RT3 – GLP3 adds glucagon receptor (GCGR) agonism to the GIP/GLP-1 dual engagement of TZ2 – GLP2, creating a triple-receptor agonist. The glucagon pathway engages energy expenditure and hepatic glucose production mechanisms not activated by dual agonists.</p><p>Q: Is RT3 – GLP3 FDA approved?</p><p>A: As of 2026, RT3 – GLP3 is in Phase 3 clinical development and is not FDA-approved. Research-grade RT3 – GLP3 is for laboratory use only.</p><p>Q: What purity is appropriate for RT3 – GLP3 research?</p><p>A: ≥99% HPLC purity with LC-MS confirmation of molecular weight and identity. TX Research Peptides supplies RT3 – GLP3 at this standard.</p><p>Related: RT3 – GLP3 Product Page → | TZ2 – GLP2 Research Guide → | Cagrilintide Research Guide → | GLP-1 Research Overview →</p>